Global Mitotic Inhibitors Market , By Indication (Breast CancerLung CancerBlood Cancer, Others), Drug Class (Taxanes, Vinca Alkaloids, Colchicine, Podophyllotoxins, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Mitotic Inhibitors Market Analysis and Size
The global mitotic inhibitors market is expected to witness significant growth during the forecast period. The factors that boosted the growth of mitotic inhibitors market are increasing cases of cancer such as lung cancer and breast cancer and aging population. These are used to treat several types of cancer using chemotherapy. These drugs are largely targeted at cancer cells to stop multiplication and help to eradicate cancer. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global mitotic inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
A mitotic drug is a type of pharmaceutical drug that blocks cell growth by restricting the cell division or mitosis. In addition to this, these drugs act by interfering with microtubules, which is a receptor that is responsible for pulling the cell apart when it split. It is extensively used in cancer treatment, especially for breast cancer patients.
Mitotic Inhibitors Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Indication (Breast Cancer, Lung Cancer, Blood Cancer, Others), Drug Class (Taxanes, Vinca Alkaloids, Colchicine, Podophyllotoxins, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Takeda Pharmaceutical Company Limited (Japan), Akorn, Incorporated (U.S.) Torrent Pharmaceuticals Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.) |
|
Market Opportunities |
|
Global Mitotic Inhibitors Market Dynamics
Drivers
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as many of the products are available in capsule and tablet form and it is a very feasible route of administration.
- Increasing Prevalence of Breast Cancer
The rising cases of breast cancer across the world in the developed as well as under-developed countries boosts the global adrenal corticosteroid inhibitor drugs market. As per the reports of WHO, 58% of deaths caused by breast cancer mostly occur in under-developed or developing countries in the world.
Opportunities
- Increased Investments and Development
Several mitotic inhibitors are extensively used in life sciences for numerous studies such as study of chromosomes (cytogenetic). Numerous market players are investing in developing and commercializing mitotic inhibitor drugs to treat cancer patients and other medical conditions. Natural occurrence and efficiency to treat cancer are likely to increase the uptake of these drugs during the forecast period.
- Increasing Demand for Retail Pharmacies
The increase in the number of cancer patients led to the increase in mitotic inhibitors that are being delivered through retail pharmacies and increase in the number of retail pharmacies in developed countries create opportunities for market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are more convenient.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global mitotic inhibitors market over a forecast period.
- High Cost
The huge expenditure associated with mitotic inhibitors surely hamper the market growth.
This global mitotic inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mitotic inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Mitotic Inhibitors Market
COVID-19 has left a major global public health crisis which has impacted practically every business. Shift from healthcare infrastructure towards managing COVID-19 has led to drug launch withdrawals and delays in clinical trials.
In the post-pandemic era, the biotechnology and pharmaceutical industries are estimated to witness enormous future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will significantly impact the global mitotic inhibitors market.
Global Mitotic Inhibitors Market Scope
The global mitotic inhibitors market is segmented on the basis of indication, drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Breast Cancer
- Lung Cancer
- Blood Cancer
- Others
Drug Class
- Taxanes
- Vinca Alkaloids
- Colchicine
- Podophyllotoxins
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mitotic Inhibitors Market Regional Analysis/Insights
The global mitotic inhibitors market is analysed and market size insights and trends are provided by type, drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global mitotic inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global mitotic inhibitors market throughout the forecasted period due to the high prevalence of cancer and increased number of FDA-approved drugs.
Asia-Pacific dominates the market due to the emerging healthcare facilities, a greater number of generic manufacturer and increase in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mitotic Inhibitors Market Share Analysis
The global mitotic inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mitotic inhibitors market.
Key players operating in the global mitotic inhibitors market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Akorn, Incorporated (U.S.)
- Torrent Pharmaceuticals Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-
